TY - JOUR
T1 - Abnormal α-catenin expression in invasive breast cancer correlates with poor patient survival
AU - Nakopoulou, L.
AU - Gakiopoulou-Givalou, H.
AU - Karayiannakis, A. J.
AU - Giannopoulou, I.
AU - Keramopoulos, A.
AU - Davaris, P.
AU - Pignatelli, M.
PY - 2002
Y1 - 2002
N2 - Aims: α-Catenin is a member of the E-cadherin-catenin family of adhesion molecules whose role is essential for the function of the E-cadherin complex. In this study, we have evaluated the expression of α-catenin but also of the other catenins (β-, γ- and p120-catenin) and E-cadherin in invasive breast cancer and statistically analysed these expressions with known clinicopathological parameters, c-erbB-2 onco-protein expression and patient survival. Methods and results: Abnormal E-cadherin and β-catenin expression, especially loss of expression, was associated with lobular histological type of breast carcinomas (P = 0.03 and P = 0.01, respectively). Abnormal E-cadherin and α-catenin expression was associated with high histological grade ductal carcinomas (P = 0.01 and P = 0.03, respectively). Abnormal E-cadherin and β-catenin expression was correlated with lymph node metastases (P = 0.02 and P = 0.05, respectively), while abnormal α- and β-catenin were correlated with the advanced stage of the disease (P = 0.04 and P = 0.05, respectively). Abnormal p120-catenin expression was associated with loss of PR (P = 0.008). Survival analysis demonstrated a statistically significant association between abnormal α-catenin expression and poor patient survival (P = 0.02). When survival analysis was performed according to the different patterns of abnormal expression, statistically significant associations were seen between cytoplasmic α- and β-catenin expression and poor survival (P = 0.006 and P = 0.04, respectively). Conclusions: α-Catenin, especially its cytoplasmic expression, seems to be a more sensitive prognostic marker than the other members of the E-cadherin complex in invasive breast cancer.
AB - Aims: α-Catenin is a member of the E-cadherin-catenin family of adhesion molecules whose role is essential for the function of the E-cadherin complex. In this study, we have evaluated the expression of α-catenin but also of the other catenins (β-, γ- and p120-catenin) and E-cadherin in invasive breast cancer and statistically analysed these expressions with known clinicopathological parameters, c-erbB-2 onco-protein expression and patient survival. Methods and results: Abnormal E-cadherin and β-catenin expression, especially loss of expression, was associated with lobular histological type of breast carcinomas (P = 0.03 and P = 0.01, respectively). Abnormal E-cadherin and α-catenin expression was associated with high histological grade ductal carcinomas (P = 0.01 and P = 0.03, respectively). Abnormal E-cadherin and β-catenin expression was correlated with lymph node metastases (P = 0.02 and P = 0.05, respectively), while abnormal α- and β-catenin were correlated with the advanced stage of the disease (P = 0.04 and P = 0.05, respectively). Abnormal p120-catenin expression was associated with loss of PR (P = 0.008). Survival analysis demonstrated a statistically significant association between abnormal α-catenin expression and poor patient survival (P = 0.02). When survival analysis was performed according to the different patterns of abnormal expression, statistically significant associations were seen between cytoplasmic α- and β-catenin expression and poor survival (P = 0.006 and P = 0.04, respectively). Conclusions: α-Catenin, especially its cytoplasmic expression, seems to be a more sensitive prognostic marker than the other members of the E-cadherin complex in invasive breast cancer.
KW - Catenins (α-, β-, γ-, p120)
KW - E-cadherin
KW - Invasive breast cancer
UR - http://www.scopus.com/inward/record.url?scp=0036278085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036278085&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2559.2002.01392.x
DO - 10.1046/j.1365-2559.2002.01392.x
M3 - Article
C2 - 12047765
AN - SCOPUS:0036278085
SN - 0309-0167
VL - 40
SP - 536
EP - 546
JO - Histopathology
JF - Histopathology
IS - 6
ER -